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Abstract
Older HIV infected subjects were previously found to have significant B cell expansion during initial antiretroviral therapy in
a prospective age-differentiated cohort of older and younger ($45 vs. #30 years) HIV-infected subjects initiating
antiretroviral therapy (ART) through the AIDS Clinical Trials Group. Here to further describe this expansion, using a subset of
subjects from the same cohort, we characterized B cell phenotypes at baseline and after 192 weeks of ART in both older and
younger HIV-infected groups and compared them to uninfected age-matched controls. We also examined whether
phenotypes at baseline associated with response to tetanus and hepatitis A vaccine at 12 weeks. Forty six subjects were
analyzed in the HIV infected group (21 older, 25 younger) and 30 in the control group (15 per age group). We observed
naı ¨ve B cells to normalize in younger subjects after 192 weeks of ART, while in older subjects naı ¨ve B cells increased to
greater levels than those of controls (p=0.045). Absolute resting memory (RM) cell count was significantly lower in the older
HIV infected group at baseline compared to controls and numbers normalized after 192 weeks of ART (p,0.001). Baseline
RM cell count positively correlated with week 12 increase in antibody to tetanus vaccine among both younger and older
HIV-infected subjects combined (p=0.01), but not in controls. The age-associated naı ¨ve B cell expansion is a novel finding
and we discuss several possible explanations for this observation. Relationship between RM cells at baseline and tetanus
responses may lead to insights about the effects of HIV infection on B cell memory function and vaccine responses.
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Introduction
The effects of HIV infection on B lymphocytes include reduced
total B lymphocyte counts, hypergammaglobulinaemia and
increased risk of B cell malignancies [1–3]. Untreated HIV
infection is associated with reduced percentages of naive B cells,
increased percentages of immature transitional cells, and expan-
sion of memory B cells in the peripheral blood that exhibit
increased turnover and greater susceptibility to apoptosis [3–5].
Chronic immune activation during HIV infection may contribute
to reduced B cell function, particularly within these memory
subsets [3].
ART, especially if initiated early in infection, is associated with
recovery of total B cell counts and normalization of most B cell
subpopulations, but resting memory cell recovery is incomplete
[1,3,4]. The aging bone marrow has a reduced ability to generate
naive B cells, resulting in a diminished capacity for older
individuals to respond to neoantigens [6]. During HIV infection,
older individuals have a reduced ability to generate naive T cells,
but the effects of aging on B cells in the setting of HIV-infection is
not known [7,8]. Pensieroso et al. have previously reported
differences in distributions of B cell subsets in a cross-sectional
analysis among HIV-infected (treated and untreated) as well as
uninfected controls and elite controllers [9]. Using multivariable
analysis they investigated whether age was a factor associated with
alteration of B-cell subpopulations. Age related differences were
not a primary focus of that study and was not found to correlate
with any of the B-cell subpopulations.
In a previous study we observed that older HIV infected
subjects had a significantly lower restoration of naı ¨ve CD4 cells
upon initiation of ART, but expansion of total B cell counts, to
levels that were significantly higher than those found in age
matched HIV-uninfected controls [10]. Within the younger group
of HIV-infected subjects B cell counts normalized, but did not
expand beyond levels of HIV-uninfected young control subjects.
To better understand these observations, using a subset of subjects
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frequencies in response to ART between two age groups, and we
examined associations between subsets and the antibody responses
to vaccination with tetanus, a recall antigen, and hepA, a
neoantigen.
Methods
Study Subjects
This research was granted a formal waiver by the Institutional
Review Board at Case Western Reserve University. This analysis
involves participants with cryopreserved samples available who
enrolled into ACTG 5015, a prospective, multicenter study that
compared immune and viral responses to antiretroviral therapy
(ART) with stavudine, emtricitabine, and lopinavir/ritonavir in
ART-naı ¨ve older and younger (ages $45, and 18–30 years,
respectively) HIV-infected subjects over 192 weeks [11]. The
original ACTG 5015 cohort included 45 older and 45 younger
adults however only the first 55 subjects participated in the
immunology sub study (ACTG 5015s) that also included
immunologic markers and vaccination with tetanus and hepatitis
A. Samples (n=30) were also included from ACTG 5113, a
contemporaneous study of HIV-uninfected healthy controls [11].
The selection of samples for the current study was based on sample
availability and viability. Viable samples were available from 46
HIV infected subjects (among all study participants, including
immunology sub study participants) and 30 controls. Median ages
among the younger groups were 26 and 25 years for HIV-infected
and uninfected controls respectively, while the median age was 49
for both the older HIV-infected and uninfected controls. All HIV-
infected participants were vaccinated at baseline with tetanus
toxoid (Aventis Pasteur, Swiftwater, Pennsylvania; Lederle-Praxis,
West Henrietta, New York; or Wyeth-Ayerst, Philadelphia,
Pennsylvania, USA), and those without serologic evidence of
hepatitis A (n=24) also received hepA vaccine (Smith-Kline
Beecham, King of Prussia, Pennsylvania, USA); the uninfected
control subjects were all hepatitis A antibody negative and
received both vaccines. All study participants provided written
informed consent, and each participating study site received
approval from its designated institutional review board. The
expansion of total B cells in older adults after 192 weeks of ART
and responses to tetanus and hepatitis A vaccines were reported in
the larger cohort however B cell phenotype analysis was not done
in that study. The B cell phenotype changes in response to ART
and the correlation of vaccine responses to B cell phenotypes is a
new analysis and being reported in the current study.
Absolute B cell counts were enumerated at the time of the
original study using freshly obtained whole blood. B cell
phenotypes were measured from cryopreserved PBMCs at weeks
0 and 192 for HIV-infected participants; single time point
cryopreserved samples were available for the controls. Phenotypic
analysis using flow cytometry was performed immediately after
thawing.
B Lymphocyte Phenotypic Analysis
Surface staining of PBMCs was performed with the following
flourochrome conjugated monoclonal antibodies: anti-CD19
Pacific Blue, anti-CD10 APC, anti-CD20 APC-Cy7, anti-CD21
FITC, anti-CD27 PE (all Biolegend). Viability Live/Dead yellow
dye (Invitrogen) was added to exclude dead cells from analysis.
Whenever enough cells were available, corresponding isotype
control (Biolegend) staining was also performed. In the event of
insufficient cells to run isotype control internal gating controls
using markers that provided the cleanest separation between
populations were used. Data were acquired on LSRII flow
cytometer (BD Biosciences) and analyzed using FlowJo 7.6.4
software (Tree Star, Ashland, OR). Lymphocytes were identified
using forward and side scatter, and further gated to include only
singlet events and live cells (Figure S1). CD19+ cells were
subsequently gated to determine the following B cell subsets:
CD10+CD272 immature transitional (IT), CD102CD21+
CD272 naı ¨ve, CD102CD21+CD27+ resting memory (RM),
CD20+CD212CD27+ mature activated (MA) and CD102
CD212CD272 tissue like memory (TLM). PBMC samples with
less than 50% viability on trypan blue stain at the time of thaw or
live/dead staining were discarded. 5610
5–10
6 total events were
captured. In addition there had to be at least 1000 CD19+ cells to
analyze the B cell subsets.
Statistical Analysis
The stratified (by sex) Wilcoxon rank-sum test was used to
compare B-cell phenotypes between HIV-infected subjects and
healthy controls within each age group (at week 0 and 192 for
HIV-infected subjects; at week 0 for uninfected controls); shift
estimates and 95% confidence intervals (CIs) were obtained by
inverting this test. Associations between B cell phenotypes at
baseline and the change in antibody from baseline to week 12 were
examined by Spearman rank correlations and by linear regression
models. These examined interactions between HIV-infection
status and age group. An additional analysis stratified for sex
and race (black vs. not black) was performed. Statistical
significance was defined as p,0.05. No adjustment was made to
account for multiple testing in these analyses.
Results
Forty-six HIV-infected subjects (n=21 and 25 for older and
younger respectively) and 30 age-matched controls (n=15 each
for older and younger) were included in this analysis. Thirty eight
of 46 HIV-infected subjects completed 192 weeks of follow up (19
of 21 [90%] older; 19 of 25 [76%] younger; p=0.26). Baseline
characteristics are included in table 1. Compared with the group
of HIV-infected subjects, the uninfected healthy control group
included significantly more women (p=0.007) and significantly
fewer African-Americans and Latinos (p,0.001). Baseline total
CD4 counts were significantly lower in older HIV-infected
subjects compared to younger group (p,0.005). Baseline total
CD4 counts and naı ¨ve CD4 counts were significantly lower in
HIV-infected subjects compared to controls (p,0.001 and
p=0.005 respectively). The median log10 viral load (VL) at
baseline was not statistically different among the older HIV-
infected subjects (5.1 vs. 4.3 log10 copies/mL; p=0.32). There
were no significant age-group differences in the percentage of
subjects who achieved initial VL suppression to ,200 copies/mL
(19 of 21 [90%] older vs. 17 of 21 [81%] younger; p=0.66).
Number of subjects achieving viral suppression after 192 weeks of
therapy was not statistically different between the two group (18 of
19 [95%] older vs. 15 of 19 [79%] younger; p=0.34).
Effect of Untreated HIV Infection on B Cell Subtypes
While untreated HIV infection was associated with a trend
toward lower total B cell count among the younger, group it was
not different from uninfected age-matched controls in the older
group (p=0.05 for younger and p=0.12 older; Figure 1).
Untreated infection was associated with significantly lower naı ¨ve
B cell count in younger, but not in older subjects (p,0.001 and
p=0.11 for younger and older, respectively; Figure 1). In contrast,
RM cells were significantly lower in older subjects (p,0.001), but
B Cells in HIV and Aging
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Similarly, the older group had a significantly lower percentage of
RM component at baseline compared to the uninfected controls
(3% vs. 15%; p,0.001; Figure 2). While the IT, TLM and MA
absolute counts did not differ significantly compared to controls in
either age-group, there were intergroup differences in percentages
of these subtypes. Younger infected subjects had significantly
higher percentages of TLM (18% vs. 9%; p=0.006) and IT cells
(14% vs. 7%; p=0.02), compared to controls (Figure 2). Among
older subjects, the percentage of TLM was higher among the HIV
infected group compared to controls (17% vs. 9%; p=0.01), but
there were no significant differences in the percentages of IT or
MA cells (Figure 2).
Vaccine Antibody Responses to B cell Phenotypes at
Baseline
Higher increases in week-12 tetanus antibody from baseline
were associated with higher baseline RM counts, but this
association was only seen in HIV-infected subjects (r=0.71,
p=0.001for HIV infected subjects; Figure 3). A similar interaction
may also be the case for hepA antibody responses, where there was
a trend towards higher week-12 antibody increases from baseline
associated with higher baseline RM counts among HIV-infected
subjects (r=0.67, p=0.07 among HIV infected subjects, only;
Figure 3). This interaction was not observed among HIV-
uninfected controls. Younger subjects also had significantly higher
hepA antibody responses to vaccination, regardless of HIV
infection status (p=0.003); there were no significant age group
differences in the antibody response to tetanus vaccination. There
were no associations between the remainder of B cell phenotypes
at baseline and vaccine responses.
HIV and Age Effects on B Cells after ART
After 192 weeks of ART, the peripheral blood B cell count
normalized in younger subjects to levels comparable to those of
controls but increased significantly in older subjects to levels above
controls (p=0.80 for younger and p=0.015 for older; Figure 1).
This increase was explained by an expansion of naı ¨ve B cells
among older subjects to levels greater than those of uninfected
controls (p=0.004; Figure 1). There was a normalization of naı ¨ve
B cell numbers among younger subjects (p=0.74; Figure 1). ART
was also associated with a normalization of RM cell count in both
age-groups (p=0.69 and p=0.39 in younger and older subjects,
respectively; Figure 1). IT, TLM and MA counts remained similar
to controls after 192 weeks of ART in both age-groups.
Proportionally RM subset remained lower in the older infected
group compared to controls (7% vs. 15%, p=0.01; Figure 2).
After 192 weeks of ART, IT subset contracted in the older infected
group to levels below the uninfected controls (2% vs. 8%,
p=0.01). TLM and MA percentages declined to similar levels as
controls in both age-groups (Figure 2).
Table 1. Baseline characteristics of study participants.
HIV-infected Uninfected controls
Older Younger Older Younger
N2 1 2 5 1 5 1 5
Median age (range) 49 (48,55) 26 (23,28) 49 (46, 53) 25 (23, 28)
Sex n, (% Male) 14 (66.6) 21 (84.0) 7 (46.7) 6 (40.0)
Race n, (% Black) 15 (71.4) 20 (80.0) 2 (13.3) 5 (33.3)
CD4 count cells/mm
3 (range) 158 (35, 340) 266 (203, 430) 900 (653, 1141) 776 (630, 837)
Naı ¨ve CD4 count cells/mm
3 (range) 54 (11, 76) 101 (78, 175) 295 (226, 491) 369 (288, 417)
B cell count cells/mm
3 (range) 124 (55, 230) 124 (88, 179) 213 (125, 245) 215 (127, 269)
Log10 HIV-RNA copies/ml (range) 5.1 (4.0, 5.6) 4.3 (4.1, 5.1) - -
doi:10.1371/journal.pone.0107064.t001
Figure 1. Absolute B cell phenotype counts before and after antiretroviral therapy. Changes in absolute B cell count and B cell subset
counts at baseline before ART (light grey) and after 192 weeks of ART (dark grey) compared to their age-matched controls (black) in older and
younger groups. Only the significant P-values are marked. Bars represent median; error bars represent interquartile ranges. RM: resting memory, TLM:
tissue like memory, MA: mature activated, IT: immature transitional.
doi:10.1371/journal.pone.0107064.g001
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In the present study we sought to further understand the
previously observed expansion of peripheral blood B lymphocytes
in older subjects treated with ART [10]. Peripheral blood B
lymphocyte count increased with ART in both age groups. The
supernormal increase in B cells in the older group was a direct
result of the striking expansion of the naive B cell subset. The older
untreated HIV-infected group, which were with lower peripheral
blood RM cells compared to their age-matched controls,
experienced normalization of this subset after ART. Regarding
B cell phenotypes and vaccine responses, we found an association
between RM cell counts and recall immune response to the
tetanus vaccine, and a trend towards the same for hepA vaccine in
HIV infected subjects, but not controls. Studies have demonstrated
that ART leads to near normalization in the peripheral blood B
cell profile [1,4]. However the combined effect of aging and HIV
on B lymphocytes is not well understood. We found that after
treatment with ART, disturbances seen at baseline return to
normal in younger individuals, while older subjects continue to
exhibit unexpected differences compared to uninfected age
matched controls.
The surprising finding in our study is that the peripheral blood
naive subpopulation in older subjects expands to levels above and
beyond what is seen in age-matched uninfected subjects. This is
especially counterintuitive considering an age-related decline in
naive B cell numbers in virally uninfected subjects has been
reported [12,13]. Additionally, we have published data showing
older HIV-infected subjects had significantly fewer naı ¨ve T cells
compared to healthy age-matched controls after 192 weeks of
ART [10,11]. This divergence of super-normal vs. attenuated
immunocyte population change of naı ¨ve B cell vs. naı ¨ve CD4 cell
populations during immune reconstitution in older HIV infected
individuals is striking. A number of reasons, all of which are
Figure 2. B cell phenotype distribution before and after antiretroviral therapy. Change in phenotype distribution in old and young age
groups compared with their respective age-matched controls. 0 and 192 refer to time on ART in weeks; Ctl refer to respective age matched
uninfected controls.
doi:10.1371/journal.pone.0107064.g002
Figure 3. Correlations between antibody responses to vaccines and resting memory count at baseline in HIV infected and
uninfected controls. a. Tetanus vaccine b. Hepatitis A vaccine.
doi:10.1371/journal.pone.0107064.g003
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that there is an enhanced capacity of the bone marrow for
lymphopoiesis in response to treatment of HIV infection in older
individuals. However, decline in bone marrow proliferation
potential with age is well documented and there is no evidence
to suggest that ART may have an age-differentiated effect on
marrow potential [14]. In fact, there is some evidence to suggest
that there is decreased bone marrow output as measured by K-
deleting recombination excision circles (KRECs) despite pro-
longed ART [15]. There is evidence to suggest that increased
homeostatic proliferation of naı ¨ve B cells occurs in response to
total B cell deficit [16], though increase to levels higher than
normal would not be expected. There may also be a component of
altered differentiation in older individuals. We did in fact observe
an age-associated contraction in the percentages of IT after ART,
though whether this is related to or responsible for naı ¨ve B cell
expansion is unclear. There has been description of a phenotyp-
ically and functionally distinct, late transitional B cell subset that is
uniquely sensitive to homeostatic signals and can selectively
expand in response to environmental stimuli [17]. Since we did
not specifically look for this population we cannot make any
conclusions regarding this as possible mechanism for peripheral
naı ¨ve B cell expansion. Lastly, it is possible that there is an age-
associated anatomic redistribution of naı ¨ve B cells from lymphoid
tissues to peripheral blood in response to ART. In fact, data in
Simian Immunodeficiency Virus-Infected Rhesus Macaques sug-
gests that not only does the composition of B cell subsets differ
significantly in lymphoid tissues compared to peripheral blood, but
that there is also a dynamic exchange between compartments in
response to ART [18]. Certainly, one limitation of our study is that
we are sampling only peripheral blood and not lymphoid tissues,
so we cannot directly address the latter possibility. Due to the
limited sample availability, testing these hypotheses was beyond
the scope of the present study, and will be the focus of future
studies.
Another notable age-related difference in the present study is
the observed significantly lower peripheral blood RM counts in the
older untreated group compared to age-matched controls. There
was recovery of absolute RM counts among the older subjects after
ART even though the overall percentage of the RM component
remained lower than normal. Moir et al. have previously reported
incomplete recovery of resting memory cells despite ART [1,4]
and have speculated that normalization of the memory B cell
compartment may be feasible only in those whose therapy was
initiated during the acute or early phase of infection, as suggested
by Tetanji et al. [19]. Ruffin et al. [20] and Jiang [21] have
reasoned that microbial translocation and inflammation which has
been shown to play a role in T cell depletion may also be
important factors in the deregulated expression of pathways
involved in B cell differentiation. Whether ongoing immune
activation is responsible for incomplete restoration of memory B
cells remains a speculation.
Restoration of the RM may be especially important when
considering a positive association between RM cell count at
baseline and recall vaccine response to tetanus. The selectivity of
this relationship for HIV infection may provide insight into why
HIV-infected individuals have impaired humoral response to
tetanus vaccine compared with uninfected individuals [22–24].
Additionally, results here may help understand parameters guiding
the optimal timing of vaccination during HIV infection. It is
possible that the response to tetanus vaccine may not be as robust
if it is administered before resting memory B cells have
reconstituted in response to ART. This maybe especially
important in older adults as they have significantly lower resting
memory B cells prior to ART and in fact do show rise in absolute
resting memory counts after ART. While the exact timeline for the
memory B cell reconstitution is not known and it may be
impractical to delay vaccination for 192 weeks after ART, this
finding gives us an insight into one aspect of impaired humoral
response to tetanus vaccine in HIV, and yet another reason to start
antiretroviral therapy. We did observe a trend toward an
association between higher responses to hepA vaccine and baseline
RM counts which is of unclear significance. Responses to
neoantigen vaccines would be expected to correlate with naı ¨ve
cell numbers, an interaction that we did not observe, though
higher resting memory cell numbers may reflect upon a more
normal naı ¨ve B cell functional state.
The limitations of this study include a small sample size.
However, despite the small sample size the data show an age-
related difference between naı ¨ve B cells in response to ART as well
as a correlation between resting memory cell numbers at baseline
and response to the tetanus vaccine in HIV-infected adults. While
the HIV-infected subjects and uninfected controls were imbal-
anced in terms of race and sex, the intergroup differences that
were observed in this study in CD4 and B cell counts are consistent
with previously well-characterized HIV-associated changes. Be-
cause of imbalances in race and sex, an additional analysis
stratified for sex and race (black vs. not black) was performed and
did not significantly alter the results.
In summary, the present study demonstrates the different effects
of ART on B lymphocyte phenotypes in two different age groups.
Despite experiencing a remarkable rise in the total number of B
cells, unlike younger adults, older HIV infected individuals fail to
restore a normal B cell phenotype distribution in the setting of
ART. While there is normalization of the apoptosis-prone and
exhausted subpopulations, there is an unexpected rise in the
peripheral blood naive population in the older adults after ART.
Analysis of the functionality of these expanded naı ¨ve cells should
provide valuable insight regarding the consequence. Association
between the resting memory component at baseline and vaccine
response may have implications on the ideal timing of vaccines
requiring recall response.
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